Trial Profile

An Open Label Long-Term Safety Study of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 27 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tenapanor (Primary)
Indications Irritable bowel syndrome
Focus Adverse reactions; Registrational
Acronyms T3MPO-3
Sponsors Ardelyx

Most Recent Events

01 Nov 2023 Results of Long-term safety , published in the Neurogastroenterology and Motility
28 Sep 2023 Results presented in an Ardelyx Media Release.
28 Sep 2023 According to an Ardelyx media release, results from this trial published in the Journal of Neurogastroenterology and Motility (JNM).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com